# A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen

Source: https://onco.cc/trials/nct00295763/  
OnCo record `nct00295763` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Genzyme, a Sanofi Company, completed.

## Summary

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen is a phase 3 interventional study registered as NCT00295763 by Genzyme, a Sanofi Company, with 61 participants recorded, started 2006-05 and reaching its primary completion in 2006-07. Interventions recorded: Thyrogen (thyrotropin alfa for injection). Conditions recorded: Differentiated Thyroid Cancer.

Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00295763
- Phase: 3
- Setting: Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method.
- Sponsor: Genzyme, a Sanofi Company
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT00295763: https://clinicaltrials.gov/study/NCT00295763

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- drugs: [Thyrotropin alfa](https://onco.cc/drugs/thyrotropin-alfa/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct00295763.json